AVBP
ArriVent BioPharma, Inc.
$33.40
-0.78 (-2.28%)
At close · Jul 8
Market Cap
$1.56B
Shares
46,574,928
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$33.40
Open$33.90
Day$32.75–34.60
52W$16.10–35.83
Avg vol 30d677K
Short int7.8M · 16.8% float · 13.1d
Short vol45%
Last earningsMay 11, 2026
DataJan 2024–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+38%
above
Price vs 50-day avg
+9%
above
RSI (14)
57
neutral
MACD trend
Negative
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+52%
trailing
YTD return
+66%
this year
Relative strength
+45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
3 of 139 funds reported for Jun 30 · net +98 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.85% of float · ▲ +1.8% MoM · 13.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
139 holders — near 2-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
EPS growth
−69%
Y/Y
Balance sheet
$45.5M
net cash
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+38%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
57
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
3 of 139 funds reported for Jun 30 · net +98 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.85% of float · ▲ +1.8% MoM · 13.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
139 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $16
Now $33 · 88%
52-wk high $36
vs 200-day avg +38%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVBP
this stock
ArriVent BioPharma, Inc.
|
$1.56B | +66.0% | — | — | 16.8% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVBP | -3.9% | +9.5% | +52.0% | -3.9% | +66.0% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -3.7% | +8.7% | +44.6% | -3.7% | +56.7% |